82 FR 45866 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 189 (October 2, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 189 (October 2, 2017)
| Page Range | 45866-45867 | |
| FR Document | 2017-20991 |
[Federal Register Volume 82, Number 189 (Monday, October 2, 2017)] [Notices] [Pages 45866-45867] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-20991] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Program Project Grant P01. Date: October 23, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Teleconference Meeting). Contact Person: Ana Olariu, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-9223, [email protected]. Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders A. Date: October 23-24, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington, DC 20037. Contact Person: Natalia Strunnikova, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 402-0288, [email protected]. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; K99/R00 Review. Date: October 23, 2017. Time: 11:30 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Crystal City, 2399 Jefferson Davis Highway, Arlington, VA 22202. Contact Person: Elizabeth A. Webber, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-1917, [email protected]. Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders B. Date: October 26-27, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD 21231. Contact Person: Birgit Neuhuber, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-9223, [email protected]@nih.gov. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) Program. Date: October 30-31, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Monaco, 700 F Street NW., Washington, DC 20001. Contact Person: William Benzing, Ph.D., Scientific Review Officer, Scientific Review [[Page 45867]] Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-0660, [email protected]. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; BPN Review Meeting. Date: November 3, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Glover Park Hotel, 2505 Wisconsin Avenue NW., Washington, DC 20007. Contact Person: Joel Saydoff, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-9223, [email protected]. Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders K. Date: November 6, 2017. Time: 2:00 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Shanta Rajaram, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 435-6033, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: September 26, 2017. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017-20991 Filed 9-29-17; 8:45 am] BILLING CODE 4140-01-P
![45866 Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices
analogues of monamine transporters to themselves (i.e. have low abuse Date: October 23, 2017.
treat substance use disorders and sleep liability). Time: 8:00 a.m. to 6:00 p.m.
disorders within the scope of the This notice is made in accordance Agenda: To review and evaluate grant
with 35 U.S.C. 209 and 37 CFR part 404 applications.
Licensed Patent Rights’’. Comments/
Place: National Institutes of Health,
Objections were not received in and incorporates by reference: Neuroscience Center, 6001 Executive
response to the NOITG. After ‘‘Prospective Grant of Exclusive Option Boulevard, Rockville, MD 20852
consideration, an exclusive license was License: Potent and Selective Analogues (Teleconference Meeting).
granted to EncepHeal with a Licensed of: Monamine Transporters; Methods of Contact Person: Ana Olariu, Ph.D.,
Field of Use of: ‘‘Use of analogues of Making; and Uses Thereof’’ FR 80:245 Scientific Review Officer, Scientific Review
monamine transporters to treat (December 22, 2015), pp. 79595–79596. Branch, NINDS/NIH/DHHS, Neuroscience
substance use disorders within the The prospective modification of the Center, 6001 Executive Blvd., Suite 3204,
Exclusive Patent License will be royalty MSC 9529, Bethesda, MD 20892–9529, (301)
scope of the Licensed Patent Rights’’.
496–9223, ana.olariu@nih.gov.
This Notice advises the public that the bearing and may be granted unless
within fifteen (15) days from date of this Name of Committee: National Institute of
NIH intends to modify the Licensed
Neurological Disorders and Stroke Initial
Field of Use originally granted to published notice, the National Institute
Review Group; Neurological Sciences and
EncepHeal. Specifically, the National on Drug Abuse receives written Disorders A.
Institute on Drug Abuse is proposing to evidence and argument that establishes Date: October 23–24, 2017.
modify the Licensed Field of Use to be that the grant of modification to the Time: 8:00 a.m. to 6:00 p.m.
‘‘use of a lead compound to treat one or license would not be consistent with the Agenda: To review and evaluate grant
more of the following: Substance use requirements of 35 U.S.C. 209 and 37 applications.
disorders, cognitive deficits, sleep CFR Part 404. Place: Melrose Hotel, 2430 Pennsylvania
disorders, attention deficit hyperactivity Complete applications for a license in Avenue NW., Washington, DC 20037.
the field of use filed in response to this Contact Person: Natalia Strunnikova,
disorder and depressive disorders. The
notice will be treated as objections to Ph.D., Scientific Review Officer, Scientific
modification to the Licensed Field of Review Branch, NINDS/NIH/DHHS,
Use in the Exclusive Patent License the grant of the contemplated
Neuroscience Center, 6001 Executive Blvd.,
requires EncepHeal to select a lead modification to Exclusive Patent Suite 3204, MSC 9529, Bethesda, MD 20892–
compound for each of the disorders License. Comments and objections 9529, (301) 402–0288, natalia.strunnikova@
listed in the Field of Use and that upon submitted to this notice will not be nih.gov.
selection of a lead compound for a made available for public inspection Name of Committee: National Institute of
disorder, the other compounds of the and, to the extent permitted by law, will Neurological Disorders and Stroke Special
technology will become available for not be released under the Freedom of Emphasis Panel; K99/R00 Review.
licensing to other companies. Information Act, 5 U.S.C. 552. Date: October 23, 2017.
Time: 11:30 a.m. to 1:30 p.m.
The technology is directed to novel Dated: September 22, 2107.
Agenda: To review and evaluate grant
analogues of modafinil. Modafinil Richard U. Rodriguez, applications.
(marketed as Provisil in United States) Associate Director, Technology Transfer Place: Hilton Crystal City, 2399 Jefferson
is approved by FDA to treat narcolepsy Center, National Cancer Institute. Davis Highway, Arlington, VA 22202.
and other sleep disorders. Modafinil has [FR Doc. 2017–21048 Filed 9–29–17; 8:45 am] Contact Person: Elizabeth A. Webber,
been studied as a possible treatment for BILLING CODE 4040–01–P Ph.D., Scientific Review Officer, Scientific
cognitive dysfunction in disorders such Review Branch, NINDS/NIH/DHHS,
as attention-deficit hyperactivity Neuroscience Center, 6001 Executive Blvd.,
disorders (ADHD) as well as cocaine DEPARTMENT OF HEALTH AND Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–1917, webbere@mail.nih.gov.
and methamphetamine addiction. HUMAN SERVICES
However, it has a relatively low affinity Name of Committee: National Institute of
National Institutes of Health Neurological Disorders and Stroke Initial
for dopamine transporter (DAT) and is Review Group; Neurological Sciences and
water-insoluble, thus requiring large Disorders B.
National Institute of Neurological
doses to achieve pharmacological Date: October 26–27, 2017.
Disorders and Stroke; Notice of Closed
effects. Early studies indicated that Time: 8:00 a.m. to 6:00 p.m.
Meetings
modafinil reduced cocaine intake more Agenda: To review and evaluate grant
effectively than placebo; however, Pursuant to section 10(d) of the applications.
subsequent larger studies reported only Federal Advisory Committee Act, as Place: Admiral Fell Inn, 888 South
modest effectiveness in reducing amended, notice is hereby given of the Broadway, Baltimore, MD 21231.
cocaine intake. The library of Contact Person: Birgit Neuhuber, Ph.D.,
following meetings.
Scientific Review Officer, Scientific Review
compounds in the technology are The meetings will be closed to the Branch, NINDS/NIH/DHHS, Neuroscience
analogs of modafinil and are designed to public in accordance with the Center, 6001 Executive Blvd., Suite 3204,
have higher affinities for DAT and provisions set forth in sections MSC 9529, Bethesda, MD 20892–9529, (301)
improved water solubility. The National 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 496–9223, neuhuber@ninds.nih.gov@nih.gov.
Institute on Drug Abuse has conducted as amended. The grant applications and Name of Committee: National Institute of
preliminary experiments on many of the the discussions could disclose Neurological Disorders and Stroke Special
compounds and has identified several confidential trade secrets or commercial Emphasis Panel; Ruth L. Kirschstein National
compounds that have higher affinities property such as patentable material, Research Service Award (NRSA) Institutional
than modafinil for the DAT and lower and personal information concerning Research Training Grant (T32) Program.
sradovich on DSK3GMQ082PROD with NOTICES
affinity than modafinil for several other individuals associated with the grant Date: October 30–31, 2017.
off target receptors. Preliminary studies applications, the disclosure of which Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
at the National Institute on Drug Abuse would constitute a clearly unwarranted applications.
indicate that some of the compounds invasion of personal privacy. Place: Hotel Monaco, 700 F Street NW.,
have in vivo activity in rodents to Name of Committee: National Institute of Washington, DC 20001.
inhibit cocaine taking behavior and are Neurological Disorders and Stroke Special Contact Person: William Benzing, Ph.D.,
not selectively self-administered Emphasis Panel; Program Project Grant P01. Scientific Review Officer, Scientific Review
VerDate Sep<11>2014 19:01 Sep 29, 2017 Jkt 244001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\02OCN1.SGM 02OCN1](https://thefederalregister.org/doc/82_FR_46055/page/1.svg)
![Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices 45867
Branch, NINDS/NIH/DHHS, Neuroscience individuals associated with the grant notify the Contact Person listed below
Center, 6001 Executive Blvd., Suite 3204, applications, the disclosure of which in advance of the meeting.
MSC 9529, Bethesda, MD 20892–9529, (301) would constitute a clearly unwarranted
496–0660, benzingw@mail.nih.gov. Name of Committee: Muscular Dystrophy
invasion of personal privacy. Coordinating Committee.
Name of Committee: National Institute of
Name of Committee: Arthritis and Type of meeting: Open Meeting.
Neurological Disorders and Stroke Special
Emphasis Panel; BPN Review Meeting. Musculoskeletal and Skin Diseases Initial Date: December 5, 2017.
Date: November 3, 2017. Review Group; Arthritis and Musculoskeletal Time: 1:00 p.m. to 2:30 p.m. *Eastern
Time: 8:00 a.m. to 6:00 p.m. and Skin Diseases Clinical Trials Review Time*
Agenda: To review and evaluate grant Committee. Agenda: The purpose of this meeting is to
applications. Date: October 24, 2017. bring together committee members,
Place: Glover Park Hotel, 2505 Wisconsin Time: 8:00 a.m. to 5:00 p.m. representing government agencies, patient
Avenue NW., Washington, DC 20007. Agenda: To review and evaluate grant advocacy groups, other voluntary health
Contact Person: Joel Saydoff, Ph.D., applications. organizations, and patients and families to
Scientific Review Officer, Scientific Review Place: Bethesda North Marriott, 5701 update one another on progress relevant to
Branch, NINDS/NIH/DHHS, Neuroscience Marinelli Road, Rockville, MD 20852. the Action Plan for the Muscular
Center, 6001 Executive Blvd., Suite 3204, Contact Person: Kathy Salaita, SCD, Chief, Dystrophies.
MSC 9529, Bethesda, MD 20892–9529, (301) Scientific Review Branch, National Institute Place: National Institutes of Health, 6001
496–9223, joel.saydoff@nih.gov. of Arthritis and Musculoskeletal and Skin Executive Boulevard, Rockville, MD 20852
Diseases, DHHS/National Institutes of Health, (Telephone Conference Call).
Name of Committee: National Institute of
6701 Democracy Blvd., Rm. 818, Bethesda, Call-In Number: 1–650–479–3208.
Neurological Disorders and Stroke Initial
MD 20892, 301–594–5033 (office), 301–402– Public Access Code: 622 734 375.
Review Group; Neurological Sciences and
Disorders K. 2406 (fax), Kathy.Salaita@nih.gov. Contact Person: Glen Nuckolls, Ph.D.,
Date: November 6, 2017. Name of Committee: National Institute of Program Director, National Institute of
Time: 2:00 a.m. to 3:30 p.m. Arthritis and Musculoskeletal and Skin Neurological Disorders and Stroke, NIH, 6001
Agenda: To review and evaluate grant Diseases Special Emphasis Panel; AMSC Executive Boulevard, Room 2203, Rockville,
applications. Conflict Review Meeting. MD 20892, Phone: (301) 496–5876, Email:
Place: National Institutes of Health, Date: October 26, 2017. nuckollg@ninds.nih.gov.
Neuroscience Center, 6001 Executive Time: 11:00 a.m. to 1:30 p.m. Prior to the meeting, an agenda will be
Boulevard, Rockville, MD 20852 (Telephone Agenda: To review and evaluate grant posted to the MDCC Web site:
Conference Call). applications. www.mdcc.nih.gov.
Contact Person: Shanta Rajaram, Ph.D., Place: National Institute of Arthritis and (Catalogue of Federal Domestic Assistance
Scientific Review Officer, Scientific Review Musculoskeletal and Skin Diseases, 6701 Program Nos. 93.853, Clinical Research
Branch, NINDS/NIH/DHHS, Neuroscience Democracy Boulevard, Suite 816, Bethesda, Related to Neurological Disorders; 93.854,
Center, 6001 Executive Blvd., Suite 3204, MD 20892 (Teleconference). Biological Basis Research in the
MSC 9529, Bethesda, MD 20892–9529, (301) Contact Person: Nakia C. Brown, Ph.D., Neurosciences, National Institutes of Health,
435–6033, rajarams@mail.nih.gov. Scientific Review Officer, 6701 Democracy HHS)
(Catalogue of Federal Domestic Assistance Boulevard, Room 816, Bethesda, MD 20892,
301–827–4905, brownnac@mail.nih.gov. Dated: September 26, 2017.
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854, (Catalogue of Federal Domestic Assistance Sylvia L. Neal,
Biological Basis Research in the Program Nos. 93.846, Arthritis, Program Analyst, Office of Federal Advisory
Neurosciences, National Institutes of Health, Musculoskeletal and Skin Diseases Research, Committee Policy.
HHS) National Institutes of Health, HHS) [FR Doc. 2017–20990 Filed 9–29–17; 8:45 am]
Dated: September 26, 2017. Dated: September 26, 2017. BILLING CODE 4140–01–P
Sylvia L. Neal, Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Program Analyst, Office of Federal Advisory
Committee Policy. Committee Policy. DEPARTMENT OF HEALTH AND
[FR Doc. 2017–20991 Filed 9–29–17; 8:45 am] [FR Doc. 2017–20989 Filed 9–29–17; 8:45 am]
HUMAN SERVICES
BILLING CODE 4140–01–P BILLING CODE 4140–01–P National Institutes of Health
Center for Scientific Review; Notice of
DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND Closed Meetings
HUMAN SERVICES HUMAN SERVICES
Pursuant to section 10(d) of the
National Institutes of Health National Institutes of Health Federal Advisory Committee Act, as
amended, notice is hereby given of the
National Institute of Arthritis and Office of the Secretary; Notice of following meetings.
Musculoskeletal and Skin Diseases; Meeting The meetings will be closed to the
Notice of Closed Meetings public in accordance with the
Pursuant to section 10(d) of the
Pursuant to section 10(d) of the Federal Advisory Committee Act, as provisions set forth in sections
Federal Advisory Committee Act, as amended, notice is hereby given of a 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
amended, notice is hereby given of the meeting of the Muscular Dystrophy as amended. The grant applications and
following meetings. Coordinating Committee. the discussions could disclose
The meetings will be closed to the The meeting will be open to the confidential trade secrets or commercial
public in accordance with the public and accessible by teleconference property such as patentable material,
sradovich on DSK3GMQ082PROD with NOTICES
provisions set forth in sections and live WebEx. Members of the public and personal information concerning
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., who wish to participate using WebEx individuals associated with the grant
as amended. The grant applications and should contact the Contact Person listed applications, the disclosure of which
the discussions could disclose on this notice for the WebEx details. would constitute a clearly unwarranted
confidential trade secrets or commercial Individuals who plan to participate and invasion of personal privacy.
property such as patentable material, need special assistance, such as Name of Committee: Center for Scientific
and personal information concerning reasonable accommodations, should Review Special Emphasis Panel; PAR Panel:
VerDate Sep<11>2014 19:01 Sep 29, 2017 Jkt 244001 PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\02OCN1.SGM 02OCN1](https://thefederalregister.org/doc/82_FR_46055/page/2.svg)
Document Created: 2017-09-30 04:40:45
Document Modified: 2017-09-30 04:40:45
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | October 23, 2017. | |
| FR Citation | 82 FR 45866 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR